Literature DB >> 19958227

NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.

Ari S Nowacek1, Reagan L Miller, Joellyn McMillan, Georgette Kanmogne, Michel Kanmogne, R Lee Mosley, Zhiya Ma, Sabine Graham, Mahesh Chaubal, Jane Werling, Barrett Rabinow, Huanyu Dou, Howard E Gendelman.   

Abstract

BACKGROUND: Factors limiting the efficacy of conventional antiretroviral therapy for HIV-1 infection include treatment adherence, pharmacokinetics and penetration into viral sanctuaries. These affect the rate of viral mutation and drug resistance. In attempts to bypass such limitations, nanoparticles containing ritonavir, indinavir and efavirenz (described as nanoART) were manufactured to assess macrophage-based drug delivery.
METHODS: NanoART were made by high-pressure homogenization of crystalline drug with various surfactants. Size, charge and shape of the nanoparticles were assessed. Monocyte-derived macrophage nanoART uptake, drug release, migration and cytotoxicity were determined. Drug levels were measured by reverse-phase high-performance liquid chromatography.
RESULTS: Efficient monocyte-derived macrophage cytoplasmic vesicle uptake in less than 30 min based on size, charge and coating was observed. Antiretroviral drugs were released over 14 days and showed dose-dependent reduction in progeny virion production and HIV-1 p24 antigen. Cytotoxicities resulting from nanoART carriage were limited.
CONCLUSION: These results support the continued development of macrophage-mediated nanoART carriage for HIV-1 disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19958227      PMCID: PMC2837804          DOI: 10.2217/nnm.09.71

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  49 in total

1.  Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.

Authors:  Huanyu Dou; Christopher J Destache; Justin R Morehead; R Lee Mosley; Michael D Boska; Jeffrey Kingsley; Santhi Gorantla; Larisa Poluektova; Jay A Nelson; Mahesh Chaubal; Jane Werling; James Kipp; Barrett E Rabinow; Howard E Gendelman
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

Review 2.  Appearance-related side effects of HIV-1 treatment.

Authors:  Trevor Hawkins
Journal:  AIDS Patient Care STDS       Date:  2006-01       Impact factor: 5.078

3.  Epidermal Langerhans cells are not principal reservoirs of virus in HIV disease.

Authors:  D C Kalter; J J Greenhouse; J M Orenstein; S M Schnittman; H E Gendelman; M S Meltzer
Journal:  J Immunol       Date:  1991-05-15       Impact factor: 5.422

Review 4.  Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms.

Authors:  L G Epstein; H E Gendelman
Journal:  Ann Neurol       Date:  1993-05       Impact factor: 10.422

5.  Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence.

Authors:  Llúcia Alòs; Pilar Navarrete; Vanesa Morente; Felipe Garcia; Marta Garrido; Montse Plana; Anna Mozos; Anna López; Cristina Gil; Tomás Pumarola; Miguel Caballero; Jose L Blanch; Emilio Fumero; José M Miró; Teresa Gallart; José M Gatell; Elias Campo
Journal:  Mod Pathol       Date:  2005-01       Impact factor: 7.842

6.  Low atazanavir concentrations in cerebrospinal fluid.

Authors:  Brookie M Best; Scott L Letendre; Eileen Brigid; David B Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; David M Simpson; Ronald Ellis; Edmund V Capparelli; Igor Grant
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

7.  Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS.

Authors:  Huanyu Dou; Cassi B Grotepas; JoEllyn M McMillan; Christopher J Destache; Mahesh Chaubal; Jane Werling; James Kipp; Barrett Rabinow; Howard E Gendelman
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

8.  HIV-1 activates proinflammatory and interferon-inducible genes in human brain microvascular endothelial cells: putative mechanisms of blood-brain barrier dysfunction.

Authors:  Anathbandhu Chaudhuri; Fenghai Duan; Brenda Morsey; Yuri Persidsky; Georgette D Kanmogne
Journal:  J Cereb Blood Flow Metab       Date:  2007-10-17       Impact factor: 6.200

9.  Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice.

Authors:  David M Taylor; Catrin Fischetti; Anna Sparshatt; Arwel Thomas; Delia Bishara; Victoria Cornelius
Journal:  J Clin Psychiatry       Date:  2008-11-18       Impact factor: 4.384

10.  Risperidone long-acting injection: a review of its long term safety and efficacy.

Authors:  Michael K Rainer
Journal:  Neuropsychiatr Dis Treat       Date:  2008-10       Impact factor: 2.570

View more
  65 in total

1.  Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.

Authors:  Ari S Nowacek; JoEllyn McMillan; Reagan Miller; Alec Anderson; Barrett Rabinow; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2010-03-17       Impact factor: 4.147

2.  Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage.

Authors:  Rafael F Bressani; Ari S Nowacek; Sangya Singh; Shantanu Balkundi; Barrett Rabinow; Joellyn McMillan; Howard E Gendelman; Georgette D Kanmogne
Journal:  Nanotoxicology       Date:  2010-12-22       Impact factor: 5.913

Review 3.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

4.  Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice.

Authors:  Christopher J Destache; Todd Belgum; Michael Goede; Annemarie Shibata; Michael A Belshan
Journal:  J Antimicrob Chemother       Date:  2010-08-21       Impact factor: 5.790

5.  Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles.

Authors:  Yuling Zhao; Matthew J Haney; Natalia L Klyachko; Shu Li; Stephanie L Booth; Sheila M Higginbotham; Jocelyn Jones; Matthew C Zimmerman; R Lee Mosley; Alexander V Kabanov; Howard E Gendelman; Elena V Batrakova
Journal:  Nanomedicine (Lond)       Date:  2011-01       Impact factor: 5.307

6.  UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.

Authors:  Jiangeng Huang; Nagsen Gautam; Sai Praneeth R Bathena; Upal Roy; JoEllyn McMillan; Howard E Gendelman; Yazen Alnouti
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-07-01       Impact factor: 3.205

7.  Macrophage endocytic trafficking of antiretroviral nanoparticles.

Authors:  Irena Kadiu; Ari Nowacek; Joellyn McMillan; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2011-03-21       Impact factor: 5.307

8.  Laser ablation for pharmaceutical nanoformulations: Multi-drug nanoencapsulation and theranostics for HIV.

Authors:  Ajay Singh; Hilliard L Kutscher; Julia C Bulmahn; Supriya D Mahajan; Guang S He; Paras N Prasad
Journal:  Nanomedicine       Date:  2020-02-13       Impact factor: 5.307

Review 9.  Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.

Authors:  Maria M Bednar; Christa Buckheit Sturdevant; Lauren A Tompkins; Kathryn Twigg Arrildt; Elena Dukhovlinova; Laura P Kincer; Ronald Swanstrom
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

10.  Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.

Authors:  Nagsen Gautam; Upal Roy; Shantanu Balkundi; Pavan Puligujja; Dongwei Guo; Nathan Smith; Xin-Ming Liu; Benjamin Lamberty; Brenda Morsey; Howard S Fox; Joellyn McMillan; Howard E Gendelman; Yazen Alnouti
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.